正在招募
Phase 1
药物
clinicaltrials.gov
NCT05403554
海外临床试验导航
肺癌
帮助用户从非小细胞肺癌、小细胞肺癌、常见驱动基因和治疗线数开始检索海外公开临床试验。
Synced trials
当前同步到的治疗类试验
以下记录来自公开临床试验数据库，已按招募状态、治疗目的、干预类型和癌症相关性做初步过滤。本站不判断患者是否符合入组条件，请以官方页面、医生和研究团队意见为准。
招募状态和入组条件可能随时变化。请以官方页面、医院和研究机构信息为准，并带给主治医生或肿瘤科医生讨论。
状态
全部
试验阶段
全部
治疗类型
全部
国家/地区
全部
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06461156
A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
正在招募
Phase 3
手术/操作放疗
clinicaltrials.gov
NCT02468024
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
正在招募
Phase 2
其他放疗
clinicaltrials.gov
NCT06311981
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT04928846
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05099172
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07085091
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
即将招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT07517640
Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07410611
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
正在招募
阶段未标明
其他放疗
clinicaltrials.gov
NCT06114108
Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06977074
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06253871
A Phase 1/1b Study of IAM1363 in HER2 Cancers
正在招募
Phase 2
药物
clinicaltrials.gov
NCT03915678
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07329322
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06780839
Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07231575
Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC
正在招募
Phase 1
器械药物放疗
clinicaltrials.gov
NCT06124118
Tumor Treating Fields for Locally Advanced NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06724263
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT05613452
Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06224387
CTS2190 Phase I /II Clinical Study in Patients
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06476093
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07377916
Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06773507
Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT06731907
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07027514
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05627960
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05613413
A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)
即将招募
Phase 4
药物
clinicaltrials.gov
NCT07671560
Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT05076760
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07230405
A Phase II Study of SKB571 in Patients With Lung Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07541170
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07542704
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT04375904
'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07227168
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06043817
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06031688
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06475755
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07500285
Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07361510
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07638891
A Study of HDM2020 in Patients With Advanced Sq-NSCLC
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT05429463
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07020221
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05686434
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07286942
Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07669779
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07100080
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06839105
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04410796
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07639242
Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC
正在招募
Phase 3
生物制剂药物手术/操作
clinicaltrials.gov
NCT04181060
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06939127
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07450183
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05668650
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06299371
Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06728865
Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06641609
A Phase I Study of CFT8919 in Patients With Advanced NSCLC
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07640789
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT05142189
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
即将招募
Phase 2
Dietary_Supplement药物
clinicaltrials.gov
NCT05703997
FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06668103
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07253142
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT05522660
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07046923
A Study of LY4175408 in Participants With Advanced Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06927986
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05955105
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06239194
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06306456
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07414953
A Phase Ib Study of HS-10504 Combined Therapy in NSCLC
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07410494
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07349537
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07361705
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06128551
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07145255
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
正在招募
Phase 2
联合产品
clinicaltrials.gov
NCT06403111
FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC
正在招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT06718309
Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07551414
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
正在招募
Phase 1
诊断检测药物
clinicaltrials.gov
NCT07660055
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT05144698
RAPA-201 Therapy of Solid Tumors
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06379087
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05985655
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06445881
Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07428044
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05949606
A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
正在招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT07264647
Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)
正在招募
Phase 2, Phase 3
生物制剂药物手术/操作
clinicaltrials.gov
NCT06616584
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
正在招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT07309952
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06644768
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06882174
This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06670196
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT07003490
Radical Resection With Contralateral Lymph Node Dissection for Clinical N3 NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07070440
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05487391
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06741085
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07156604
Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07358689
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT03778814
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04429087
A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT05104515
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
正在招募
Phase 3
药物其他
clinicaltrials.gov
NCT05445791
Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06875310
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06401824
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT03786003
ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07689643
Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer
即将招募
Phase 2
生物制剂手术/操作
clinicaltrials.gov
NCT07576725
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT07225036
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07244926
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
即将招募
Phase 2
联合产品器械
clinicaltrials.gov
NCT07618793
Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05800587
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07235306
Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06188650
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07416474
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
正在招募
Phase 1
联合产品药物其他
clinicaltrials.gov
NCT06789172
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07341737
SL-28 for Advanced Solid Tumours
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT03808337
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
正在招募
Phase 2
诊断检测药物
clinicaltrials.gov
NCT06902272
ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06823245
Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function
即将招募
Phase 4
药物
clinicaltrials.gov
NCT06893354
Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
即将招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07543172
CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07063329
Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
即将招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT06685653
Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06947694
A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06706219
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07583771
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04762199
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
正在招募
Phase 2
生物制剂手术/操作
clinicaltrials.gov
NCT06918132
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
即将招募
Phase 2
放疗
clinicaltrials.gov
NCT06813664
ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT04846634
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07358884
First in Human Study of QLS5316 in Solid Tumors
正在招募
Phase 1, Phase 2
器械药物
clinicaltrials.gov
NCT03953144
Synapse 3D With Intravascular Indocyanine Green
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07207395
A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
即将招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07670312
Evaluation of XYA02 in Patients With Advanced Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT05501665
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07348965
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06969612
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05295212
Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06047379
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
正在招募
阶段未标明
药物其他
clinicaltrials.gov
NCT07337096
Electro-Acupuncture in Lung cancER : EALER Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07003321
A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT07431827
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT05378334
Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06644066
Partial Pressure of Oxygen Control Method in Identification of Intersegmental Plane
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07129161
Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06069570
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06956001
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05841472
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06562192
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07281209
A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06929936
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05341583
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05503888
Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07498595
TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06659042
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT06481566
Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT06312137
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06542159
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07134413
QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07623356
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06495125
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07630077
Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities
正在招募
Phase 1
生物制剂器械药物
clinicaltrials.gov
NCT07116057
MOv19-BBz CAR T Cells in FRa+ Cancers
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06775275
A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05765877
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
即将招募
阶段未标明
手术/操作放疗
clinicaltrials.gov
NCT07432802
Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07554846
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06772623
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07365410
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05351788
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06015568
Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07391813
SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07180862
A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04322890
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07685041
An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT05620342
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
正在招募
阶段未标明
联合产品
clinicaltrials.gov
NCT06238882
Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT04852588
Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06775483
Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT06709274
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT04105270
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06434740
A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07064018
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06885840
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05532696
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT04614103
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT06734702
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT04966663
Using ctDNA to Determine Therapies for Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07140016
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
正在招募
Phase 2
行为干预生物制剂药物
clinicaltrials.gov
NCT07288034
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06242470
A Study of MGC026 in Participants With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06147570
A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06614231
Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07271602
A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07619339
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07103395
A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
正在招募
Phase 2
生物制剂手术/操作
clinicaltrials.gov
NCT07017829
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06568939
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07453394
QLS5132 Combination Therapy in Advanced Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07172802
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06980272
SSGJ-707 in Advanced Non-Small Cell Lung Cancer
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07252739
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT05234307
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
即将招募
Phase 2
放疗
clinicaltrials.gov
NCT07679607
GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04930432
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT05642572
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05283330
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07202611
DC/NK Cell Therapy
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07590531
AMT-116 in Combination With Ivosidan in Patients With Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07412262
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04977453
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
正在招募
Phase 3
生物制剂药物其他
clinicaltrials.gov
NCT07554339
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
正在招募
Phase 1
药物其他
clinicaltrials.gov
NCT04297605
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07223424
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07680790
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06498986
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07405190
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07158489
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
即将招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT06067776
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06901817
A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06071013
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07169734
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06241807
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07438600
Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07330596
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
即将招募
Phase 3
药物
clinicaltrials.gov
NCT05767892
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07624214
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
即将招募
Phase 1
药物
clinicaltrials.gov
NCT05940116
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
正在招募
Phase 2, Phase 3
药物其他
clinicaltrials.gov
NCT07034326
Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
正在招募
Phase 3
联合产品
clinicaltrials.gov
NCT07016126
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07154368
JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07020117
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT01639508
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
正在招募
Phase 1
药物手术/操作
clinicaltrials.gov
NCT06249282
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07034391
A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06403735
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05589818
Pembrolizumab for Advanced NSCLC and PS 2-3
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07231068
A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05751018
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT07164885
RAPART in Locally Advanced Non-small Cell Lung Cancer Patients
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07105176
HS-IT101 Injection for Advanced NSCLC
即将招募
Phase 4
药物
clinicaltrials.gov
NCT07674368
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06625775
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05713006
Alectinib Pharmacokinetic in Patients With NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07171606
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07432984
Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07339839
Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT04944563
Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07610798
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
正在招募
Phase 2
器械药物
clinicaltrials.gov
NCT06305715
Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07108816
A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)
即将招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07551778
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06693336
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06436144
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05752552
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04951635
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06928389
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
即将招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06202690
SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06745908
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07036185
A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07151040
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07182682
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06627738
Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost
正在招募
Phase 3
生物制剂其他
clinicaltrials.gov
NCT06077760
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06607796
Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06931626
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07227025
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06996782
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06837948
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06501378
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07292168
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT07528274
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06537297
Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT06422143
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06532591
Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06060613
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
正在招募
Phase 4
药物
clinicaltrials.gov
NCT06561620
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06943820
AK129 Combination Therapy for Advanced Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06564324
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07082179
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT03392233
Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06284317
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06171750
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06244771
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06774963
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06892548
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
正在招募
Phase 2
其他放疗
clinicaltrials.gov
NCT04405401
Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT06788912
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
正在招募
Phase 1, Phase 2
药物放疗
clinicaltrials.gov
NCT07535463
A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07483983
Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT05468242
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07208773
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
正在招募
Phase 2
其他手术/操作放疗
clinicaltrials.gov
NCT06660407
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06731413
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07043907
PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05061550
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07110363
A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07486817
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07089199
Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
正在招募
Phase 1
药物
clinicaltrials.gov
NCT02570815
Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT05800340
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06195189
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07117890
Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
正在招募
Phase 1, Phase 2
药物手术/操作
clinicaltrials.gov
NCT05543330
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07599163
Oral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II Trial
即将招募
Phase 2
联合产品药物
clinicaltrials.gov
NCT07274384
Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06357533
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07158840
AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06350097
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
正在招募
Phase 4
药物
clinicaltrials.gov
NCT07320105
Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT07132190
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
即将招募
Phase 3
药物
clinicaltrials.gov
NCT05990127
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06969027
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07354061
Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06083870
An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC
正在招募
Phase 2
生物制剂药物放疗
clinicaltrials.gov
NCT06667908
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07573696
Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy
即将招募
阶段未标明
生物制剂
clinicaltrials.gov
NCT06643910
A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT06305962
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT06538012
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06963502
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07361237
A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06517953
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05950139
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06977828
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT06463665
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06936644
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT06780098
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
正在招募
Phase 1
联合产品药物
clinicaltrials.gov
NCT07358806
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06484816
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06663306
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06908733
Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04332367
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
即将招募
Phase 1
放疗
clinicaltrials.gov
NCT07523464
Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06331455
Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06855771
A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07247227
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05288205
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05715229
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04270591
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07038460
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT05098210
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07192068
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05401110
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06793813
Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06632262
A Phase 2 Clinical Study of ABSK061 and ABSK043
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04499053
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06769295
A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
正在招募
Phase 2
联合产品药物
clinicaltrials.gov
NCT07014202
Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy
正在招募
Phase 2
药物其他手术/操作
clinicaltrials.gov
NCT06617936
Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.
即将招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT07318636
NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05011487
Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
正在招募
Phase 1, Phase 2
联合产品药物
clinicaltrials.gov
NCT07371663
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06971406
High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07154706
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07397338
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06848699
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04144569
PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT03872661
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05431270
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06205927
Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07464327
A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06974370
Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04728724
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06864624
Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05186506
A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06784193
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07609121
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05366478
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
正在招募
Phase 3
器械药物
clinicaltrials.gov
NCT05317858
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07085182
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06612840
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
正在招募
Phase 3
联合产品
clinicaltrials.gov
NCT05852990
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06586515
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04777084
The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07586826
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06784791
Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06793215
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06922591
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
即将招募
Phase 3
药物手术/操作放疗
clinicaltrials.gov
NCT04465968
Efficacy and Safety of CRT, Durvalumab and Surgery for SST
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07650357
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06427941
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
即将招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT06944470
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
正在招募
Phase 2
生物制剂药物放疗
clinicaltrials.gov
NCT05657873
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06596915
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06878274
Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07298148
Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06747585
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07452224
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT06848426
Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06589778
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07269782
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07659782
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07561723
IMP3-saRNA Vaccine in Advanced NSCLC
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07414927
A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06667154
Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT04686305
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07444437
A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07294261
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07139041
Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05394831
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07489716
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06487078
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06492421
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT06607926
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT05229614
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07094204
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06185400
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06198907
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT03191149
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04980716
Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06999187
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07379398
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07586202
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06300177
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
正在招募
Phase 3
器械药物
clinicaltrials.gov
NCT06216301
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06295432
A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05920356
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05989542
A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06080776
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07662811
SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07560358
Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT03193567
Study of High Efficient Killing Cell Therapy for Advanced NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06465329
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07410975
Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT06634056
Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07197853
Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT05753722
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06897046
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
正在招募
Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT06731270
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06822543
A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05789082
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
即将招募
Phase 3
联合产品药物
clinicaltrials.gov
NCT07135882
Primary Radiotherapy In MEtastatic Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07183189
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06905197
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06643000
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05254184
KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07538193
Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06106802
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT06903377
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06394674
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06315010
REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06421298
A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06667167
First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07189871
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07076914
Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06043466
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07178795
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
即将招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06127329
Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07503808
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06364917
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07242274
Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT04302025
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06745882
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT03175224
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
即将招募
Phase 2
联合产品药物
clinicaltrials.gov
NCT07603791
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07631884
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07115043
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
即将招募
Phase 2
放疗
clinicaltrials.gov
NCT07670715
Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT03769129
Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06961201
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06730295
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer
正在招募
阶段未标明
器械手术/操作
clinicaltrials.gov
NCT07479277
Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07234877
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05669430
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07086456
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06388031
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
正在招募
Phase 1
药物手术/操作放疗
clinicaltrials.gov
NCT06800339
A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06749860
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06890182
Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT04933903
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07154290
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07084610
Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04316364
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06992609
Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
即将招募
Phase 3
药物
clinicaltrials.gov
NCT04772287
Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)
即将招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06679712
Transbroncheal Novel PDT Peripheral Lung Tumor Ablation With 5-ALA
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06908772
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05856981
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
正在招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT05766800
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06102928
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07153445
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05492682
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
即将招募
阶段未标明
放疗
clinicaltrials.gov
NCT07462728
Phase III, Multicenter, Randomized Controlled Clinical Study of Three-Dimensional Radiotherapy for Primary Tumors in Non-Oligometastatic Stage IV Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07058519
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07227298
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
正在招募
Phase 2
器械药物手术/操作
clinicaltrials.gov
NCT05672108
Phase II Trial of Lung Chemoemobolization
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06955325
Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT07195084
To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06775678
Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05132985
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
正在招募
Phase 1, Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT07641023
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06709859
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07037680
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06917573
PALACE: Cemiplimab Trial According to ctDNA Levels
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT06951646
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06585059
Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT07660094
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07106827
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04999761
AB122 Platform Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07518160
JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
即将招募
Phase 4
生物制剂手术/操作
clinicaltrials.gov
NCT07633613
Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06262321
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07435038
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06323148
Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05281406
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
即将招募
Phase 2
生物制剂手术/操作
clinicaltrials.gov
NCT07393555
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06692738
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06417814
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06908304
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07086326
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05379985
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06416410
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT06840782
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06706076
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07343479
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06092086
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07250386
A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07622186
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
正在招募
Phase 1, Phase 2
药物放疗
clinicaltrials.gov
NCT04789486
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05435248
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06431633
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT06228326
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06192849
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
即将招募
Phase 1
其他手术/操作
clinicaltrials.gov
NCT06743555
Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07601048
A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05956587
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
正在招募
Phase 3
生物制剂
clinicaltrials.gov
NCT06767514
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07574684
Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06335355
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07415005
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06868485
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06598839
Immuno-effect of Tα1 for Stage I NSCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06890598
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
即将招募
Phase 3
药物放疗
clinicaltrials.gov
NCT07608159
Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.
即将招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07597070
Universal Immunization to Fortify Immunotherapy Efficacy and Response
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06930794
A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07561983
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05671510
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07175220
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
正在招募
Phase 1, Phase 2
药物放疗
clinicaltrials.gov
NCT06814496
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07452003
An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT05060796
Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06043973
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06702826
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06131840
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07545213
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07153770
Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT05834413
Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors
即将招募
Phase 1
基因治疗
clinicaltrials.gov
NCT07461727
An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06476808
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07423117
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07185997
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06970782
Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07379476
Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07642024
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06754644
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06865339
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06634667
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06218914
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
正在招募
Phase 3
药物其他
clinicaltrials.gov
NCT07150663
Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06970639
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05940532
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT03742687
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07314216
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06567015
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
正在招募
Phase 4
药物
clinicaltrials.gov
NCT05525338
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06426511
ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04691817
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06858813
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06982924
A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05107674
A Study of NX-1607 in Adults With Advanced Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07001618
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07566052
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
即将招募
Phase 3
药物其他
clinicaltrials.gov
NCT06858410
Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
正在招募
Phase 2
手术/操作
clinicaltrials.gov
NCT05837052
A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06048315
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06561685
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT01720836
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05568212
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
即将招募
Phase 2
药物
clinicaltrials.gov
NCT04153734
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06577792
Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06109558
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06627647
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
正在招募
Phase 4
药物
clinicaltrials.gov
NCT07279935
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06926413
A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06829459
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07177105
Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06672068
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05123482
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07614646
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC Patients
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT06616623
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05241028
Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05286957
MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT04973293
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05014464
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07361484
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06841055
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06269211
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06114511
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07170995
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06282536
Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04389632
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06530719
A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07030257
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07617337
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07229339
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
正在招募
Phase 2
其他手术/操作放疗
clinicaltrials.gov
NCT06008730
Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07540572
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
正在招募
Phase 2, Phase 3
放疗
clinicaltrials.gov
NCT02448992
Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07035392
Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07195695
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06028633
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04969315
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07439094
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06001151
Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative
正在招募
Phase 3
生物制剂药物其他
clinicaltrials.gov
NCT06345729
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06355609
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06823258
Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT05278052
Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07362940
A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07493980
Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06946836
Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05271916
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06728852
Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06066138
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07014215
PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06467617
Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
正在招募
Phase 2
药物其他手术/操作
clinicaltrials.gov
NCT07293247
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
正在招募
Phase 3
手术/操作放疗
clinicaltrials.gov
NCT06500455
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06899126
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
即将招募
Phase 2, Phase 3
药物其他
clinicaltrials.gov
NCT07149649
Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06896890
Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer
正在招募
阶段未标明
药物放疗
clinicaltrials.gov
NCT06484491
IMPT Dose Escalation for NSCLC (HyDose)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06868836
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06962865
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
正在招募
Phase 1, Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT05269381
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06618391
Local Injection and Systemic Therapy in the Treatment of NSCLC.
正在招募
Phase 2
生物制剂手术/操作
clinicaltrials.gov
NCT06116682
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05654454
A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06228482
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06687369
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07144280
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06924606
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06956690
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07204548
The IVO-LUNG Study
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT06639191
[177Lu]Lu-AKIR001 First-in-human Study
正在招募
Phase 2
联合产品
clinicaltrials.gov
NCT07130032
Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT03093688
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06563999
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
正在招募
Phase 4
药物
clinicaltrials.gov
NCT05748093
Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT05344209
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT05623267
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05983432
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
正在招募
Phase 3
生物制剂其他
clinicaltrials.gov
NCT07513376
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
正在招募
Phase 3
药物其他
clinicaltrials.gov
NCT05211895
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07193641
A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC
即将招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07322341
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05104788
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06734182
Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06156527
A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06362369
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06835569
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
正在招募
阶段未标明
器械药物
clinicaltrials.gov
NCT05987345
Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05473156
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07688577
XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors
正在招募
Phase 2, Phase 3
药物其他
clinicaltrials.gov
NCT07063745
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
正在招募
Phase 1
药物放疗
clinicaltrials.gov
NCT03546829
Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT03556228
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
正在招募
Phase 1, Phase 2
生物制剂诊断检测
clinicaltrials.gov
NCT06051695
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07200947
A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
正在招募
Phase 1
生物制剂联合产品
clinicaltrials.gov
NCT04282044
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
正在招募
Phase 1, Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07012031
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
即将招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07562581
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05005403
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07087223
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07322783
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT01803542
Stereotactic Radiotherapy (SBRT) of Lung Metastasis
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06576635
LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients
正在招募
阶段未标明
手术/操作放疗
clinicaltrials.gov
NCT02984761
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
正在招募
Phase 4
药物
clinicaltrials.gov
NCT06908070
Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT05502523
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07232420
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06123754
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07418866
FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06694454
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06604351
Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06828757
Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07261631
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06755684
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05742607
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06404164
Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06150664
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06706713
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06680050
Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07127874
A Study of PHN-012 in Patients With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05498428
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07351565
Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05245500
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07283198
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07264816
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
即将招募
Phase 2
放疗
clinicaltrials.gov
NCT05548504
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06883552
An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT05570825
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04683250
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04853342
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07603661
Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07376707
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT07467863
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07122687
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06667076
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
正在招募
Phase 3
药物其他
clinicaltrials.gov
NCT06141070
Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07070518
Study of GV20-0251 in Participants With Solid Tumor Malignancies
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07164313
A Study of ZW251 in Participants With Advanced Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05910827
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07491497
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06496490
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT06127303
Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06792435
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05786924
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07507188
Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06455917
TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07277413
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07548060
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT05557552
Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06735391
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07174908
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07219576
Retifanlimab and Ruxolitinib In Solid Malignancies
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07622706
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT04486833
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
正在招募
Phase 1
药物
clinicaltrials.gov
NCT03917043
APG-2449 in Patients With Advanced Solid Tumors
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT06545747
Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07020065
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT06735508
MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04996121
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT03460977
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06467500
A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06512207
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07177092
Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06877299
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07627321
Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06254599
A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07336732
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07534033
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07169552
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07133425
A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07360743
Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels
即将招募
Phase 3
手术/操作
clinicaltrials.gov
NCT07617389
Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer (SCIENCE Study)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06422403
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06046495
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
正在招募
EARLY / Phase 1
放疗
clinicaltrials.gov
NCT06712745
Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06514027
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT07505173
Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07198841
IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT05800223
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07181473
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07304739
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07079475
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07462377
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06343402
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
即将招募
Phase 2
生物制剂其他手术/操作
clinicaltrials.gov
NCT06943664
Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06813365
Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04335292
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
正在招募
Phase 3
生物制剂
clinicaltrials.gov
NCT06868277
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06424067
Phase 2 Study of Fingolimod in Lung Cancers
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05275374
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04467723
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
正在招募
Phase 1
生物制剂药物其他
clinicaltrials.gov
NCT05681780
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06221462
Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06617416
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07360132
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT05198830
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT07468071
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06375109
PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05597800
Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07285148
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07361562
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04606446
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
即将招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06454890
Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT07286149
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07308106
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06868732
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06863506
Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06943521
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07416058
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
正在招募
Phase 1, Phase 2
放疗
clinicaltrials.gov
NCT04210492
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07619911
SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06275360
Repositioning Immunotherapy in VetArans With Lung Cancer
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT06598527
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07376382
A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05913089
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06838273
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06849167
Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC
即将招募
阶段未标明
器械药物
clinicaltrials.gov
NCT06969781
MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06485557
A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06623136
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06109402
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07498439
TILs Therapy for Multiple Primary Early-Stage NSCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05382728
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06652529
Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors
正在招募
阶段未标明
其他手术/操作放疗
clinicaltrials.gov
NCT05802186
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
正在招募
阶段未标明
联合产品
clinicaltrials.gov
NCT07398599
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06424899
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05086692
A Beta-only IL-2 ImmunoTherapY Study
即将招募
Phase 2
联合产品
clinicaltrials.gov
NCT07241819
Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06022757
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
正在招募
Phase 3
其他手术/操作放疗
clinicaltrials.gov
NCT06500481
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05669846
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07169994
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07250477
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06861543
The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)
正在招募
Phase 3
器械药物
clinicaltrials.gov
NCT04585490
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07224152
NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07111520
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06925048
SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06142617
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
即将招募
Phase 2
行为干预药物手术/操作
clinicaltrials.gov
NCT07472478
Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07288177
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07031154
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07182708
High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06590194
PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07120698
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT05296564
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07413952
Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06032052
Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06752408
Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06343064
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05267626
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07190027
Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06452277
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
即将招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06646770
SEgmentectomy Versus Lobectomy in T1C Non-Small Cell Lung Cancer (SELTIC)
正在招募
Phase 1, Phase 2
药物放疗
clinicaltrials.gov
NCT07594522
A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05873686
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07193160
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06789796
a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT07132918
HEARTS Trial for Thoracic Cancers
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07284186
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07402070
IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07249372
DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06119581
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07463677
Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07306624
Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06918782
Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT05493566
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06917079
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
即将招募
Phase 1
手术/操作放疗
clinicaltrials.gov
NCT06982222
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
正在招募
Phase 3
器械药物
clinicaltrials.gov
NCT06472245
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07623369
A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06674343
Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06319313
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06775743
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07140315
DK222 Study at Hopkins
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04585750
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT07613723
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
正在招募
Phase 2
生物制剂手术/操作
clinicaltrials.gov
NCT06620835
Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07362459
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
正在招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT06810609
Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06010329
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05334277
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06998719
Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07578571
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07655622
Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07148128
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06582771
A Study of Sotorasib in People With Non-Small Cell Lung Cancer
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT05378633
The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06552234
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07206498
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06682884
Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06141226
Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06714708
Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06582940
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT05877599
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06417008
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07392658
Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06380348
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
正在招募
Phase 3
其他放疗
clinicaltrials.gov
NCT06686771
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06908993
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07083687
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07382726
Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT06528743
Feasibility of Primer Shot Radiotherapy for Non-small Cell Lung Cancer - PRIMER
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07223047
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05967689
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06594874
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06926790
Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06501391
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
正在招募
Phase 1
药物放疗
clinicaltrials.gov
NCT06116786
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07602842
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06362980
A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05469022
Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05393466
BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06688656
Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06319950
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05777278
Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06631989
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04865250
Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06026410
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07146230
The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06225804
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06618287
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07442565
SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ
正在招募
Phase 1, Phase 2
生物制剂诊断检测
clinicaltrials.gov
NCT06682793
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05937906
Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06456138
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07554859
GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05948813
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06040541
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06683703
Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06525350
A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07440290
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT05891080
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT05136846
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
即将招募
Phase 1
手术/操作
clinicaltrials.gov
NCT06602661
Reinforced and Non-Reinforced Staple Lines in Fissureless Lobectomy
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06972576
Clinical Study of Combined EphA2-targeted CAR-DC and CAR-T Cell Therapy for Non-small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06962189
The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07675876
Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05482568
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
正在招募
阶段未标明
生物制剂其他
clinicaltrials.gov
NCT07652125
RGL-270 + ICI in Advanced NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06528847
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07155187
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05276726
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07517198
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07224971
Impact of Circadian Rhythm on Immunotherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06924398
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06236438
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05227326
AOH1996 for the Treatment of Refractory Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06210815
A Study of HLX42 in Advanced/Metastatic Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06430437
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07420439
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06102057
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT07612722
Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06249854
Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT05584267
Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06847334
A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT05837767
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT06630611
Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07680764
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07348211
First in Human Study of SIM0610 in Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06810544
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07181499
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07216105
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06895031
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05398094
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07109531
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07489703
SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC
即将招募
Phase 1
药物放疗
clinicaltrials.gov
NCT06760676
A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07318883
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06120283
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07001995
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07661173
A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06561386
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05538130
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06581419
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07005102
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07291037
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
正在招募
Phase 3
药物手术/操作
clinicaltrials.gov
NCT06632327
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT04631770
Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT07052669
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06304441
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06486142
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05377658
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07567326
Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07332858
First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07485452
Boosting Osimertinib Blood Brain Barrier Penetration
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06444815
A Study of VET3-TGI in Patients With Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07160335
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT06020430
Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT07594067
TCR1188-ABC Cells in KRAS-mutated Cancers
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07489066
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06090266
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
正在招募
Phase 1
生物制剂器械药物
clinicaltrials.gov
NCT06529822
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06851169
This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07459283
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06018688
Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07482605
Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07647094
A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer
正在招募
Phase 2
基因治疗
clinicaltrials.gov
NCT05536505
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06620822
Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07418931
A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07609251
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06448754
Volrustomig Priming Regimens Exploratory Phase II Platform Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06440954
Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05168566
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06616766
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07039656
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07459751
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07229729
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT07222566
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06779539
Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07631299
Nebulized AER101 in Pre-op NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06452433
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07323732
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07596121
Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%
正在招募
阶段未标明
器械手术/操作
clinicaltrials.gov
NCT06732193
Fissios© and Postoperative Complications (FPoC Trial)
即将招募
Phase 4
药物
clinicaltrials.gov
NCT06785584
Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study
即将招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07683832
Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07383116
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
正在招募
Phase 4
药物
clinicaltrials.gov
NCT03340506
Dabrafenib and/or Trametinib Rollover Study
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07444814
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05085028
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07375316
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07579221
Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer
即将招募
Phase 2
药物其他
clinicaltrials.gov
NCT07550920
Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05805631
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06448572
EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06754930
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT04616209
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT05798845
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07217301
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06473961
A Phase Ib Study of GC101 in NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06987734
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06951464
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05024214
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06162221
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05467748
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07472647
SYS6090 Combination Therapy in Advanced Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07623642
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07408635
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07668752
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06332755
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT05724004
Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07098338
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07232849
A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06881784
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06574347
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06652048
High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05825443
Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients
即将招募
Phase 1
生物制剂手术/操作放疗
clinicaltrials.gov
NCT07619599
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05098132
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07365319
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05751798
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
即将招募
Phase 3
药物其他
clinicaltrials.gov
NCT07477808
Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07064876
Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06218940
HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07323056
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT05236946
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07589205
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07633873
SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）
即将招募
Phase 4
联合产品
clinicaltrials.gov
NCT07469488
A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT04787042
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT04992780
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05284539
Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT05255302
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06953843
Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT04875585
Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07630168
Effects of Infusion Timing on Treatment Response in Solid Tumors
即将招募
Phase 1
放疗
clinicaltrials.gov
NCT06622174
Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04317534
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06690671
A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT04165070
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT02133196
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
正在招募
Phase 3
生物制剂
clinicaltrials.gov
NCT05899608
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT07412327
Prospective Phase II Clinical Study of Stereotactic Body Proton Therapy (SBPT) for Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07198217
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07563738
A 2-part Phase 1/2 Open-label Trial on ODM-212
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT04147078
Personalized DC Vaccine for Postoperative Cancer
正在招募
Phase 3
药物其他
clinicaltrials.gov
NCT07010263
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07353476
Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07390838
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07637448
EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT06780085
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06931717
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05859217
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05361174
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07138755
The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06697990
Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07629960
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07662395
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT06743581
Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06512051
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07355205
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06545331
Study of XB010 in Subjects With Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06281678
A Study of IBI363 in Subjects with Advanced Solid Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04701476
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06041776
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
即将招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT07327736
Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT
即将招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07560111
A Phase II Study of GC101 in NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06992739
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
即将招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT06580665
Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07090499
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06088771
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06475300
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07202364
A Study of YL202 in Patients With Advanced Solid Tumors
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07162883
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06276283
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07603856
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06738160
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
即将招募
Phase 3
药物其他
clinicaltrials.gov
NCT06961188
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07098988
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07418879
A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06007937
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
正在招募
Phase 4
药物手术/操作
clinicaltrials.gov
NCT07405086
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07492342
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
即将招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07247786
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07056556
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05706129
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05363280
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07096882
SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06934590
Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT05033691
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases
正在招募
Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT07221474
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07672223
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
正在招募
Phase 2, Phase 3
药物其他
clinicaltrials.gov
NCT07131319
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06378892
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07535437
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06765109
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT03412877
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06363734
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07330037
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06336954
Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07558200
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07315113
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07164170
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06746870
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06634979
Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06524427
Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
正在招募
Phase 3
生物制剂药物其他
clinicaltrials.gov
NCT06623422
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT02889666
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07300150
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05979818
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06579196
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06955988
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06747169
Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study
即将招募
Phase 2
其他手术/操作
clinicaltrials.gov
NCT07333651
125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04136535
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07361497
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07636785
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07486648
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07416994
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05815173
Ladarixin With Sotorasib in Advanced NSCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05176483
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06623656
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT06557096
CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07549061
Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06303505
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05379803
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05504278
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06907615
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06449313
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06644313
Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06868849
A Study of JMT203 in Patients With Cancer Cachexia
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06352008
To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
即将招募
阶段未标明
放疗
clinicaltrials.gov
NCT05998993
Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT05277844
Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
正在招募
Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT07246863
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT07564557
Septum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04077099
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06621563
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT07565987
A Phase II Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07495098
Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06248606
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07458347
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06585644
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07538804
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07242547
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07256509
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05758116
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
正在招募
Phase 1
药物放疗
clinicaltrials.gov
NCT04550104
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT04322617
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT06437977
Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06758401
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT05355701
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05777603
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07120282
Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06182761
A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT06523673
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06946927
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07330050
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06266299
A Study of KK2269 in Adult Participants With Solid Tumors
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06712316
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06656598
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05631249
Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
即将招募
Phase 4
药物
clinicaltrials.gov
NCT06276933
A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
正在招募
Phase 1
药物手术/操作
clinicaltrials.gov
NCT04780568
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06704620
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT05754203
Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05902988
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06348927
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
正在招募
Phase 3
生物制剂其他手术/操作
clinicaltrials.gov
NCT07388524
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
正在招募
Phase 3
手术/操作
clinicaltrials.gov
NCT06031246
Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06554613
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT05484583
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05271292
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06838208
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07083375
A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06371482
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07103408
A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07006727
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05978284
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07402343
Tarlatamab for SCLC Brain Metastases
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07636226
QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT06529081
Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07416695
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06784206
Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer
正在招募
Phase 2, Phase 3
生物制剂药物
clinicaltrials.gov
NCT07226999
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
即将招募
Phase 4
药物
clinicaltrials.gov
NCT07485920
A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06773910
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07551635
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06258642
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06469879
A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07398560
Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
即将招募
Phase 4
药物
clinicaltrials.gov
NCT06951841
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06769971
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06970795
A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05490472
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06786312
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06648200
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07502300
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07296809
SKB500 Combinations in Patients With Small Cell Lung Cancer
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT04696575
Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07365241
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07339059
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT06646276
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
即将招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07172412
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT05150145
Radiotherapy or Observation of Liver Metastases in Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06125041
Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06348797
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06527898
Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT04342429
Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
正在招募
Phase 4
药物
clinicaltrials.gov
NCT05874401
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07203053
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07177937
A Study of DXC014 in Patients With Advanced Solid Tumors.
正在招募
Phase 1, Phase 2
放疗
clinicaltrials.gov
NCT06243003
WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05903092
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07373964
A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
正在招募
Phase 1
放疗
clinicaltrials.gov
NCT07139990
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07637513
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06807632
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07538258
Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07625644
Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT07480213
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07424547
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06496048
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT04952480
Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06620796
A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07141264
Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07155174
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06820762
Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06223711
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06943235
Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT06462105
Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07038096
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06581380
JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05963867
A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06922539
ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07425795
Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07069270
A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07559929
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07509034
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06911606
Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05588388
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05718323
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05652686
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06663098
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06914050
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04539977
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07005128
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07057791
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06236997
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07531095
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07583511
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT05552846
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06177925
A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07037758
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07547332
Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06758700
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07357532
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
正在招募
Phase 1, Phase 2
药物放疗
clinicaltrials.gov
NCT06217757
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06030258
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
正在招募
Phase 1
药物放疗
clinicaltrials.gov
NCT07113691
Iadademstat + SBRT With Atezo in ES-SCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06498479
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06203210
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07153055
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06562920
Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07472517
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06505824
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT03467360
Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07061535
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07501169
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06853678
Second-line Immunotherapy for ES-SCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06497530
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05450965
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06179069
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05924841
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
正在招募
Phase 3
联合产品放疗
clinicaltrials.gov
NCT06457906
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
正在招募
Phase 2, Phase 3
药物手术/操作放疗
clinicaltrials.gov
NCT04402788
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06429696
PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06480864
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05703971
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07646106
THE-0504 in Patients With Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06805825
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
正在招募
Phase 2
手术/操作放疗
clinicaltrials.gov
NCT05419076
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07407933
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05745350
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07016230
Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06247605
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07107490
A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05578326
Study of Trilaciclib and Lurbinectidin
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07227597
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06613009
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06719700
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04951947
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06614621
A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06485544
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
即将招募
Phase 3
药物放疗
clinicaltrials.gov
NCT06719336
Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)
正在招募
Phase 1, Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06110572
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07206563
Penfluridol for Relapsed/Refractory Small Cell Cancers
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06749691
Liposomal Irinotecan and Apatinib in ES-SCLC
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07488923
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06536868
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06475209
Adebrelimab + Apatinib in SCLC Maintenance Therapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07632209
Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT04919382
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07349225
Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06801834
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06283719
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06954246
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物其他
clinicaltrials.gov
NCT07278479
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06256237
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06479811
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07640932
Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05957510
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
正在招募
Phase 2
联合产品
clinicaltrials.gov
NCT07358676
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06483282
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06698965
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07559786
A Multicenter, Randomized, Cohort, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06610734
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06769126
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06497543
Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07559019
Safety and Preliminary Activity of BI115 in Advanced SCLC
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06526624
A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07545954
DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07476287
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT07008716
Omitting CTV for Primary Tumor in LS-SCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06437509
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06902350
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06771518
Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04699838
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06739928
Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06793228
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07249879
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06780137
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07231445
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07325136
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06597513
Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT04790253
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06586957
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
正在招募
Phase 3
其他放疗
clinicaltrials.gov
NCT04829708
Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07110103
Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
正在招募
Phase 1, Phase 2
药物放疗
clinicaltrials.gov
NCT06479473
Radiotherapy to All Residual Lesions After Chemoimmunotherapy
正在招募
Phase 1, Phase 2
联合产品药物
clinicaltrials.gov
NCT06681220
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06554535
Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer
即将招募
Phase 4
药物
clinicaltrials.gov
NCT06931145
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06873555
A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06332950
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07038343
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07376499
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT07443397
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06295926
Serplulimab Combined With CCRT for LS-SCLC.
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06978153
This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05623319
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06441344
Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07218146
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
正在招募
Phase 2
器械药物
clinicaltrials.gov
NCT05882058
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT05068232
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06095583
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06851819
Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07459634
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07258147
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07200154
Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06909383
Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07465757
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
正在招募
Phase 1, Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06287775
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
正在招募
Phase 4
药物
clinicaltrials.gov
NCT06467786
Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07091305
A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06362252
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07063407
Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06830694
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06095505
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07174583
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07149363
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06768307
Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07388875
Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC
正在招募
Phase 1
药物放疗
clinicaltrials.gov
NCT05244239
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07097948
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07289048
A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07381543
Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07155200
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
正在招募
Phase 3
放疗
clinicaltrials.gov
NCT07015892
Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07564401
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07141771
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06592638
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05904015
The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
即将招募
Phase 3
联合产品
clinicaltrials.gov
NCT05496166
The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06128837
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07080242
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06712355
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07055581
Durvalumab as Consolidation for Patients LS-SCLC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07189455
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07022301
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07654400
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07583550
Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07245446
A Study of Ivonescimab in First-Line ES-SCLC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06306560
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07538271
A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07004712
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07413042
A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07246304
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07109401
Perioperative Immunotherapy for Resectable Limited-Stage SCLC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06424665
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
即将招募
Phase 3
药物放疗
clinicaltrials.gov
NCT06672133
Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT07099898
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07076095
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06440057
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07550842
A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06383728
Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05778149
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07458919
Therapy for Advanced NSCLC With EGFR 19delins Mutation
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04085315
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07295821
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04591002
Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07197008
Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis
第 1 页
没有符合当前筛选条件的试验。
Subtypes
建议拆分方向
非小细胞肺癌 NSCLC小细胞肺癌 SCLC转移性肺癌 metastatic lung cancer晚期肺癌 advanced lung cancerEGFR mutationALK rearrangementROS1KRAS G12CRETMET exon 14PD-L1First lineSecond line
Keyword guide
这些关键词怎么理解
| 术语 | 中文意思 | 对找临床试验有什么用 |
|---|---|---|
| 非小细胞肺癌 / Non-small cell lung cancer / NSCLC | 肺癌中最常见的一大类，和小细胞肺癌在治疗方式、常见基因突变和试验设计上不同。 | 很多试验会明确只招 NSCLC 患者，或进一步限定 EGFR、ALK、KRAS 等突变状态。 |
| 小细胞肺癌 / Small cell lung cancer / SCLC | 一种生长较快、治疗路径和非小细胞肺癌不同的肺癌类型。 | 搜索时通常要单独使用 SCLC 或 small cell lung cancer，不要只搜 lung cancer。 |
| EGFR mutation | EGFR 基因突变是肺癌常见驱动基因之一，常见于部分非小细胞肺癌患者。 | 可以找 EGFR 靶向药、耐药后治疗、exon 19 deletion、L858R、exon 20 insertion 等相关试验。 |
| ALK rearrangement | ALK 融合或重排是一类肺癌驱动基因改变。 | 可以找 ALK 抑制剂、耐药后治疗、新一代 ALK 药物等相关试验。 |
| KRAS G12C | KRAS 基因的一种具体突变类型，在部分非小细胞肺癌中出现。 | 可以找 KRAS G12C 抑制剂、联合治疗或耐药后治疗相关试验。 |
| PD-L1 | 一种和免疫治疗选择有关的生物标志物，通常由病理或检测报告给出表达水平。 | 很多免疫治疗试验会要求 PD-L1 表达水平，或按表达水平分层。 |
| 转移性肺癌 / metastatic lung cancer | 癌症已经扩散到肺以外的远处器官，比如脑、骨、肝、肾上腺等。 | 很多海外试验会限定 metastatic 或 advanced 患者，需要和影像报告一起确认。 |
| First line | 一线治疗，通常指晚期或转移后第一次系统治疗方案。 | 试验可能要求患者尚未接受过晚期一线治疗，或只接受过特定治疗。 |
| Second line | 二线治疗，通常指一线治疗失败、进展或不能耐受后更换的下一套方案。 | 很多试验会写 after progression on first-line therapy，需要准备既往治疗记录。 |
Recruitment status
常见招募状态
| Recruiting | 正在招募，可能仍可申请参加。 |
| Not yet recruiting | 尚未开始招募，可关注后续开放时间。 |
| Active, not recruiting | 试验仍在进行，但通常不再招新患者。 |
| Completed | 试验已经完成。 |
| Terminated | 试验提前终止。 |
| Unknown | 公开页面上的状态不明确或未及时更新。 |
Before contact
联系前准备资料
- 病理诊断报告
- 影像报告：CT / MRI / PET-CT
- 既往治疗记录
- 用药历史
- 基因检测报告
- 最近血液检查结果
- 出院小结
- 主治医生英文病情摘要，如果有
- 护照和签证情况，如果考虑出国
Filters
搜索时重点关注
- Recruiting / Not yet recruiting
- Location
- Age
- Phase
- Inclusion Criteria
- Exclusion Criteria
- Prior treatments
- Biomarker / mutation requirements
- ECOG performance status
- 是否接受 international patients
- 是否需要长期停留在试验所在地
- 费用、保险、翻译、住宿和陪护安排
Ask your doctor
可以带去问医生的问题
- 我的病理类型是否符合这个试验？
- 我之前用过的药会不会影响入组？
- 我是否需要做基因检测？
- 这个试验是几期？主要目的是什么？
- 参加试验会不会影响当前治疗？
- 如果去国外参加，风险和成本大概有哪些？
- 研究团队是否接受海外患者？
请将检索到的临床试验信息带给主治医生或肿瘤科医生讨论。本站不判断患者是否适合任何临床试验。